Analía Azaro

First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma

Jordi Rodón, Michael A. Carducci, Juan Manuel Sepúlveda-Sánchez et al. · Clinical Cancer Research · 2014 · 232 citations

Medicine, Oncology, Pharmacology +13

Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor–Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy

Meritxell Bellet, Kathryn P. Gray, Prudence A. Francis et al. · Journal of Clinical Oncology · 2016 · 157 citations · Full text

Medicine, Endocrinology, Oncology +17

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

Marta Palafox, Laia Monserrat, Meritxell Bellet et al. · Nature Communications · 2022 · 120 citations · Full text

Medicine, Oncology, Pharmacology +16

Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study

Richard J. Kovacs, Giuliana Maldonado, Analía Azaro et al. · Cardiovascular Toxicology · 2014 · 112 citations · Full text

Medicine, Oncology, Pharmacology +17

Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer

Jordi Rodón, Michael A. Carducci, Juan Manuel Sepúlveda-Sánchez et al. · Investigational New Drugs · 2014 · 105 citations · Full text

Medicine, Oncology, Pharmacology +17